EASTPHARMA LTD
(“the Company” or “Eastpharma”)
EASTPHARMA’S DELISTING OF ITS GDRS
Further to the Company's announcement of 2 May 2019, Eastpharma announces that the cancellation of the the standard listing of its Global Depositary Receipts (“GDRs”) on the Official List and the London Stock Exchange ("LSE") and the cancellation of the admission of the GDRs to trading on the main market of the LSE (the "LSE Delisting") is now effective as of 8.00 a.m.(London time) today, 1 August 2019.
As a result of the above, the relationship agreement entered into at the time of the IPO and made between the Company, Pharmainvest Master Account LP, Emerging Income Fund Master Account L.P., Emerging Value Opportunities Fund Master Account LP, Fursa Master Global Event Driven Fund L.P., Fursa Master European Event Driven Fund LP and DE Shaw Laminar Portfolios, L.L.C. has terminated.
Holders of the Company’s Regulation S and Rule 144A GDRs will continue to have the rights attached to such GDRs in accordance with the terms and conditions of the deposit agreement.
The Board is aware that the LSE Delisting will make it more difficult to buy and sell GDRs in the Company following the LSE Delisting. Therefore, the Company is investigating the possibility of establishing a secondary market trading facility to assist holders of GDRs to trade in the GDRs. The Company may be unable to establish a secondary trading facility. If the Company does establish such a facility details will be made available to GDR holders on the Company's website at: www.eastpharmaltd.com.
For further information, please contact:
Investor Relations:
ir@eastpharmaltd.com
EastPharma Ltd - a company active in the manufacturing and marketing of pharmaceutical products in Turkey and in other regional markets; for further information please visit www.eastpharma.com.